Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Molecular & Cellular Proteomics : MCP|March 14, 2014
Conserved peptide fragmentation as a benchmarking tool for mass spectrometers and a discriminating feature for targeted proteomicsUmut H Toprak, Ludovic C Gillet, Alessio Maiolica, et al.
Nature Communications|June 25, 2016
MYC/MIZ1-dependent gene repression inversely coordinates the circadian clock with cell cycle and proliferationAnton Shostak, Bianca Ruppert, Nati Ha, et al.
Genome Research|January 14, 2021
Accurate and efficient detection of gene fusions from RNA sequencing dataSebastian Uhrig, Julia Ellermann, Tatjana Walther, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2021
FOXR2 Stabilizes MYCN Protein and Identifies Non-<i>MYCN</i>-Amplified Neuroblastoma Patients With Unfavorable OutcomeFelix Schmitt-Hoffner, Sjoerd van Rijn, Umut H Toprak, et al.
Nature Genetics|March 26, 2021
Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastomaSelina Jansky, Ashwini Kumar Sharma, Verena Körber, et al.
Molecular Systems Biology|November 29, 2017
Screening drug effects in patient-derived cancer cells links organoid responses to genome alterationsJulia Jabs, Franziska M Zickgraf, Jeongbin Park, et al.
Life Science Alliance|March 4, 2021
Kalirin-RAC controls nucleokinetic migration in ADRN-type neuroblastomaElena A Afanasyeva, Moritz Gartlgruber, Tatsiana Ryl, et al.
Molecular & Cellular Proteomics : MCP|April 16, 2014
Modulation of the chromatin phosphoproteome by the Haspin protein kinaseAlessio Maiolica, Maria de Medina-Redondo, Erwin M Schoof, et al.
Haematologica|January 20, 2022
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilitiesNicola Giesen, Nagarajan Paramasivam, Umut H Toprak, et al.
Ebiomedicine|August 27, 2020
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastomaSally L George, Federica Lorenzi, David King, et al.
Pageof 3